Bioanalytical Systems, Inc. (NASDAQ:BASI) Stock Traded Significantly Above Its 50 Day Moving Average

0
57

The stock last traded at $1.94 which is significantly higher than the 50 day moving average which is $1.73 and which is significantly above the 200 day moving average of $1.64. The 50 day moving average was up $0.21 or +12.12% and the 200 day average went up $0.30 or +18.44%. Trading was light with 2,189 shares changing hands by the end of trading on Tuesday. Trading volume was down 92.36% under the stocks average daily volume.

Short traders are feeling a little more bullish on shares of Bioanalytical Systems, Inc. as shown by the downtick in short interest. The firm experienced a fall in short interest between September 15, 2017 and September 29, 2017 of -50.00%. Short shares fell from 20,448 to 10,224 over that period. With short interest at 10,224 and short average daily volume at 22,100, days to cover is 0.0 and the short interest percentage is 0.00% as of September 29.

Bioanalytical Systems, Inc. (NASDAQ:BASI) has been the object of insider buying activity recently. R. Matthew Neff, Director acquired $7,500 worth of shares at an average price of $1.50 on Fri the 8th. That brings the Director’s holdings to $15,000 as recorded in a recent Form 4 SEC filing. Gregory Cole Davis, Director disclosed the purchase of 5,000 shares of BASI stock. The shares were bought on August 18th for an average price of $1.70. Davis now owns $8,500 of the stock per the Form 4 SEC filing.

Director R. Matthew Neff acquired 5,000 shares at an average price of $1.70 on Fri the 18th. Neff now owns $8,500 of stock per an SEC filing yesterday.

These firms have modified their investment in BASI. Citadel Advisors LLC divested its stake by shedding 10,600 shares a decrease of 41.5%. Citadel Advisors LLC controls 14,935 shares with a value of $25,000. The value of the position overall is down by 28.6%. As of quarter end Kcg Holdings, Inc. had disposed of 10,528 shares trimming its stake by 25.4%. The value of the total investment in Bioanalytical Systems, Inc. went from $58,000 to $51,000 a change of $7,000 for the reporting period.

Ubs Group Ag trimmed its investment by selling 5,477 shares a decrease of 78.6% in the quarter. Ubs Group Ag owns 1,489 shares worth $2,000. The total value of its holdings decreased 80.0%. Acadian Asset Management LLC bolstered its position by buying 1,143 shares an increase of 9.4% from 06/30/2017 to 09/30/2017. Acadian Asset Management LLC now holds 13,336 shares valued at $23,000. The total value of its holdings increased 15.0%.

Bioanalytical systems, Inc., launched on July 17, 1975, is an international contract research company providing drug discovery and development services and analytical instruments. The Company focuses on providing drug developers with scientific research and analytical instrumentation. The Company operates in two segments: contract research services and research products. The contract research services segment provides research and development support on a contract basis to pharmaceutical companies. The research products segment provides liquid chromatography, electrochemical and physiological monitoring products to pharmaceutical companies, universities, government research centers, and medical research institutions. The Company supports the preclinical and clinical development needs of researchers and clinicians for small molecule and large biomolecule drug candidates..

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.